Not available
Quote | Blueprint Medicines Corporation (NASDAQ:BPMC)
Last: | $109.03 |
---|---|
Change Percent: | 0.0% |
Open: | $110.43 |
Close: | $109.03 |
High: | $111.89 |
Low: | $108.82 |
Volume: | 287,319 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Blueprint Medicines Corporation (NASDAQ:BPMC)
2024-06-10 07:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib) PR Newswire -- Breadth of data across 7 presentations, including 4 oral, reflects continued leadership in adv...
Message Board Posts | Blueprint Medicines Corporation (NASDAQ:BPMC)
Subject | By | Source | When |
---|---|---|---|
Why the drop today...the news release seems positive...anyone | ziggy7796 | investorshub | 08/17/2022 2:40:48 PM |
BPMC buy 98.69 | stocktrademan | investorshub | 09/12/2021 4:19:19 AM |
Blueprint Medicines Corp. | TFMG | investorshub | 06/21/2020 6:15:20 PM |
Avapritinib Today is the date | Frankestin | investorshub | 05/14/2020 10:35:40 AM |
Sold near EOD @ $59.60. Earnings pre-market tomorrow. | chmcnfunds | investorshub | 07/31/2018 7:58:12 PM |
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
2024-06-10 07:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib) PR Newswire -- Breadth of data across 7 presentations, including 4 oral, reflects continued leadership in adv...
Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting PR Newswire -- Updated Phase 1 dose escalation data show that BLU...